JCXH-211

BIOLOGICAL2 trials

Sponsors

Immorna Biotherapeutics, Inc., Duke University

Conditions

Cutaneous TumorMalignant Solid TumorRecurrent or Progressive High-grade Glioma

Phase 1

Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors

Immorna Biotherapeutics, Inc.Cutaneous Tumor, Malignant Solid Tumor

Start: 2022-10-18End: 2024-05-31Updated: 2023-04-04

Safety, Tolerability and Efficacy of JCXH-211 in Patients With Recurrent or Progressive High-Grade Glioma

WithdrawnNCT06468605

Duke UniversityRecurrent or Progressive High-grade Glioma

Start: 2025-11-01End: 2030-10-01Updated: 2025-07-23